Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

VASCUBONE · Construction kit for tailor-made vascularized boneimplants

FP7Status: CLOSED1 January 201031 March 2015EU funding €11,966,071

The goal of VascuBone is to develop a “tool box” for bone regeneration, which on one hand fulfils basic requirements and on the other hand is freely combinable with what is needed in the respective patient’s situation. The tool box will include a variation of biocompatible biomaterials and cell types, FDA approved growth factors, material modification technologies, simulation and analytical tools like molecular imaging based in vivo diagnostics which can be combined for the specific medical need. This tool box will be used to develop translational approaches for regenerative therapies of three different types of bone defects. The chosen bone diseases differ in their requirements, to ensure a successful implementation and translation. Additionally this implementation strategy is characterized by high complexity to remove bottlenecks and limitations of bone regeneration identified in the clinical setting. Therefore definite quality criteria have to be evaluated concerning an optimal stem cell source/subpopulation as well as GF concentrations and their bioactivity in vivo. Furthermore quantitative evaluation will focus on the definition of differences between stem cell populations responsible for bone regeneration in young and old people, as a prerequisite for the development of regenerative therapies for the ageing European society. Considering a successful and prompt approval of the biomaterial, for each clinical application a minimum of modification steps in daily routine must be identified. The road map of the project and clinic trials contains pre-determined milestones, to ensure efficacy, safety, and immunological acceptance of the implant. The efficacy is quantified by high innovative MRI and PET/CT technology which is able to demonstrate the regenerative effect of biomaterials and cells in vivo. Based on the clinical data the proposal as “Advanced Therapeutical Medicinal Product” will be submitted to the European Medicines Agency at the end of the project.

Consortium · 18 organisations

coordinator

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV

DE · €2,380,656

participant

MRB Forschungszentrum fur Magnet-Resonanz-Bayern e.V.

DE · €898,500

participant

JOHNSON & JOHNSON MEDICAL GMBH

DE · €129,883

participant

KUNGLIGA TEKNISKA HOEGSKOLAN

SE · €597,280

participant

UPPSALA UNIVERSITET

SE · €357,680

participant

EVONIK INDUSTRIES AG

DE · €80,258

participant

CellTech Services Götz GmbH

DE · €51,903

participant

MEDIZINISCHE UNIVERSITAT INNSBRUCK

AT · €1,172,180

participant

NANOPET PHARMA GMBH

DE · €528,156

participant

PP-POLYMER AB

SE · €431,899

participant

TOPASS GMBH

DE · €364,272

participant

MEDICYTE GMBH

DE · €742,000

participant

UNIVERSITAET INNSBRUCK

AT · €261,757

participant

OESTERREICHISCHE AKADEMIE DER WISSENSCHAFTEN

AT · €327,668

participant

JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG

DE · €1,816,592

participant

DIACOATING GMBH

AT · €374,926

participant

UNIVERSITETET I BERGEN

NO · €1,082,480

participant

KOMET RHOBEST GMBH

AT · €367,981

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.